OIA
CRSP icon

Optimum Investment Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Optimum Investment Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-400
Closed -$8K – 921
2020
Q4 		$8K Buy
+400
New +$47.3K ﹤0.01% 747

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Optimum Investment Advisors's CRSP Position: Q1 2025 in Review

Optimum Investment Advisors sold out of CRISPR Therapeutics (CRSP) in Q1 2025, closing a stake of 200 shares — an estimated $7.87K sold.

Optimum Investment Advisors first reported a position in CRSP in Q3 2019 and held it in 22 quarters. The position peaked at $49K in Q2 2021. 396 funds tracked by Wall St. Rank hold CRSP as of Q1 2025.

  • Optimum Investment Advisors reported no remaining CRISPR Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Optimum Investment Advisors sold 200 CRISPR Therapeutics shares in Q1 2025, an estimated $7.87K.
  • Optimum Investment Advisors first reported a position in CRISPR Therapeutics in Q3 2019 and held it in 22 quarters.
  • Optimum Investment Advisors's CRISPR Therapeutics position peaked at $49K in Q2 2021.
  • 396 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2025.

Based on Optimum Investment Advisors's 13F filing for Q1 2025, filed 30 Apr 2025.